1. Scrip
  2. >>Business

Lupin Expects Respiratory Ramp Up From Fiscal '22

Generics To Benefit From US Election Outcome

 
• By Vibha Ravi

After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.

Inhale,Exhale concept. Hand turns dice and changes the word "INHALE" to "EXHALE".
Lupin Is Banking On Its Respiratory Portfolio For Growth • Source: Shutterstock

Lupin Limited expects its respiratory portfolio to begin delivering growth from fiscal 2022 which starts this 1 April, although sales in the third quarter of its current financial year fell behind expectations due to a mild flu season and a slow ramp up of Glumetza (metformin) in the US.

After a generic to Teva Pharmaceutical Industries Ltd.’s blockbuster ProAir HAF (albuterol sulfate) was launched in the US during Q2, the company is planning launches of a couple more products to drive its respiratory ambitions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.